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NeurodegenerationSince the early days of mitochondrial medicine, it has been clear that optic atrophy is a very common and
sometimes the singular pathological feature in mitochondrial disorders. The ﬁrst point mutation of
mitochondrial DNA (mtDNA) associated with the maternally inherited blinding disorder, Leber's hereditary
optic neuropathy (LHON), was recognized in 1988. In 2000, the other blinding disorder, dominant optic
atrophy (DOA) Kjer type, was found associated with mutations in the nuclear gene OPA1 that encodes a
mitochondrial protein. Besides these two non-syndromic optic neuropathies, optic atrophy is a prominent
feature in many other neurodegenerative diseases that are now recognized as due to primary mitochondrial
dysfunction. We will consider mtDNA based syndromes such as LHON/dystonia/Mitochondrial Encephalo-
myopahty Lactic Acidosis Stroke-like (MELAS)/Leigh overlapping syndrome, or nuclear based diseases such
as Friedreich ataxia (mutations in FXN gene), deafness–dystonia–optic atrophy (Mohr–Tranebjerg) syndrome
(mutations in TIMM8A), complicated hereditary spastic paraplegia (mutations in SPG7), DOA “plus”
syndromes (mutations in OPA1), Charcot–Marie–Tooth type 2A (CMT2A) with optic atrophy or hereditary
motor and sensory neuropathy type VI (HMSN VI) (mutations inMFN2), and Costeff syndrome and DOAwith
cataract (mutations in OPA3). Thus, genetic errors in both nuclear and mitochondrial genomes often lead to
retinal ganglion cell death, a speciﬁc target for mitochondrial mediated neurodegeneration. Many
mechanisms have been studied and proposed as the bases for the pathogenesis of mitochondrial optic
neuropathies including bioenergetic failure, oxidative stress, glutamate toxicity, abnormal mitochondrial
dynamics and axonal transport, and susceptibility to apoptosis.© 2009 Elsevier B.V. All rights reserved.1. IntroductionRetinal ganglion cells (RGCs) are the ﬁnal output of the retina. They
project their long axons to form the optic nerve and relate the visual
information to the brain [1]. The RGCs somata resides in the inner
retina and the axons, having emerged from the cell body, enter the
retinal nerve ﬁber layer (RNFL), turn into the optic nerve head, cross
the lamina cribrosa and, emerging posterior to the ocular globe,
becomemyelinated and organized in bundles, giving form to the optic
nerve. For the long intraocular length these axons remain unmyeli-
nated and thus very energy dependent in order to transmit the action
potential. Once they achieve myelination posterior to globe, their
energy dependence decreases drastically, as they now “enjoy” the
efﬁciency of saltatory action potential conduction [2,3].
This physiological dichotomy is reﬂected in the need to distribute
the mitochondria asymmetrically, such that they are very abundant in
the intraocular unmyelinated portion, and remarkably fewer posterior
to the lamina cribrosa, where they remain in clusters under the nodes
of Ranvier or travelling towards the synaptic terminal. This function-+39 051 209 2751.
ll rights reserved.ally skewed system is probably at the basis of the extreme
vulnerability of this cell type to respiratory chain dysfunction,
oxidative stress and ultimately apoptosis [2–4]. Thus, RGCs degenera-
tion, optic nerve atrophy, and consequent blindness are very frequent
clinical features of mitochondrial disorders [5].
We here review themost relevant phenotypes, distinguishing non-
syndromic and syndromic optic neuropathies.
2. Syndromic or non-syndromic?
Leber's hereditary optic neuropathy (LHON) [6,7] and dominant
optic atrophy (DOA) [8–10] are the two most frequent mitochondrial
hereditary optic neuropathies with monosymptomatic expression
[2,11]. In contradistinction, optic neuropathy, as a part of a more
complex syndrome, is frequent in other multi-systemic mitochondrial
disorders such as the LHON/dystonia/Mitochondrial Encephalomyo-
pathy Lactic Acidosis Stroke-like (MELAS)/Leigh overlapping syn-
drome [2,12–16], or mitochondrial diseases due to genetic errors in
nuclear genes encoding mitochondrial proteins such as Friedreich
ataxia (FRDA) [17], deafness–dystonia–optic atrophy (Mohr–Traneb-
jerg) syndrome (MTS) [18], complicated hereditary spastic parapaple-
gia (HSP) associated with mutations in the SPG7 gene [19], DOA “plus”
Table 1
Disease Genetic defect Protein Function Visual defect References
Non-syndromic
Leber's hereditary optic
neuropathy (LHON, OMIM
#535000)
mtDNA genes: ND subunits of
Complex I
Respiratory chain
Complex I
Optic atrophy, central
scotoma (papillomacular
bundle), colour vision
defects, acute/subacute,
visual recovery
[2,7,11,29,30,39]
-11778/ND4
-3460/ND1
-14484/ND6
-Others
Dominant optic atrophy
(DOA, OMIM #165500)
Nuclear genes: Optic atrophy 1 (OPA1,
dynamin-like GTPase)
Mitochondrial fusion,
control of cristae
morphology and apoptosis,
maintenance of membrane
potential and OXPHOS,
stability and maintenance
of mtDNA
Optic atrophy, central
scotoma (papillomacular
bundle), colour vision
defects, congenital/slowly
progressive, no visual
recovery
[2,9–11,58,66,69]
-OPA1 (3q28-q29)
-others
Syndromic
LHON/dystonia/MELAS/Leigh
overlapping syndrome
(OMIM #500001,
540000, 256000)
mtDNA genes: missense
point mutations in
ND subunit genes
ND subunits of
Complex I
Respiratory chain
Complex I
LHON-like optic atrophy,
retinal pigmentary changes
[2,12–16,79–83]
Friedreich ataxia
(FRDA, #229300)
Nuclear gene: FXN (9q13) Frataxin Handling of iron,
chaperoning iron–sulphur
clusters; antioxidant
protection
Optic atrophy and optic
radiations involvement,
concentric restriction,
slowly progressive or
occasionally LHON-like
subacute optic neuropathy
[7,88,89, 92–94]
Mohr–Tranebjaerg syndrome
(MTS, OMIM #304700)
Nuclear gene: TIMM8A/
DDP (Xq22)
TIMM8A (translocase
of the inner membrane,
TIM)
Co-assembles with
TIMM13, necessary for the
import of TIMM23, other
unknown functions
Late optic atrophy, early
visual cortex and optic
radiations involvement
[18,96–98]
Hereditary spastic paraplegia 7
(HSP7, OMIM #607259)
Nuclear gene: SPG7
(16q24.3)
Paraplegin
(mitochondrial
metalloprotease of the
AAA family)
Quality control of
mitochondria including
stability of complex I (?)
and maturation of proteins
involved in ribosomal
assembly, proteolitic
processing of OPA1 (?)
Optic atrophy, no detailed
descriptions
[19,111–113]
Optic atrophy, deafness,
ophthalmoplegia and
myopathy (DOA plus, OMIM
#125250, 165500)
Nuclear genes: -OPA1
(3q28–q29) missense
mutations in the GTPase
domain (R445H and
others)
Optic atrophy 1 (OPA1,
dynamin-like GTPase)
Mitochondrial fusion,
control of cristae
morphology and apoptosis,
maintenance of membrane
potential and OXPHOS,
stability and maintenance
of mtDNA
Profound congenital/
childhood onset optic
atrophy
[2,20,21,124–
127]
Hereditary motor and sensory
neuropathy type VI (HMSN
VI, OMIM #601152) or
Charcot–Marie–Tooth type
2A (CMT2A, OMIM
#609260) with optic
atrophy
Nuclear gene: MFN2
(1p36.2)
Mitofusin 2 (Mfn2,
dynamin-like GTPase)
Mitochondrial fusion,
control of apoptosis,
modulation of cellular
energy balance (?)
Optic atrophy, central
scotoma (papillomacular
bundle), colour vision
defects, subacute, visual
recovery over years in cases
with late-onset, OPA1-like
optic neuropathy in
early-onset cases
[23,24]
Infantile encephalopathy
(OMIM +603850.0001)
Nuclear gene: DLP1/DRP1
(12p11.21)
Dynamin-like protein 1
(DLP1, dynamin-like
GTPase)
Mitochondrial ﬁssion,
control of apoptosis
Optic atrophy and optic
nerve hypoplasia
[116]
Optic atrophy plus Costeff
syndrome (OMIM#258501)
and Optic atrophy with
cataract (OMIM #165300)
Nuclear gene: OPA3
(19q13.2–q13.3)
Optic atrophy 3 (OPA3) Function unknown Optic atrophy, cataract [25–28]
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atrophy or hereditary motor and sensory neuropathy type VI (HMSN
VI) [22–24], and Costeff syndrome [25,26] and DOA with cataract
[27,28]. For all of these mitochondrial disorders (summarized in Table
1), we brieﬂy review the optic nerve pathology to uncover common
motifs, or to emphasize differences in the clinical expression and in the
possible mechanisms leading to optic neuropathy.
3. Non-syndromic optic neuropathies: LHON and DOA
The non-syndromic optic neuropathies, LHON and DOA, are by
deﬁnition limited to a single cellular target, i.e. the RGCs that originate
the optic nerve. Both diseases share the hallmark of early andpreferential involvement of the small axons that form the papillo-
macular bundle, the anatomical substrate for central and colour vision
[2,11].
3.1.1. LHON clinical features
Theodor Leber ﬁrst described LHON as a hereditary optic atrophy
affecting mostly youngmales [6]. It is nowwell established that LHON
is maternally inherited, being due to the three frequent pathogenic
mtDNA point mutations at positions 11778/ND4, 3460/ND1, and
14484/ND6 [7,29,30]. Epidemiological studies demonstrated that
LHON is the most frequent mitochondrial disease [31]. LHON patients
present with rapid and painless loss of central vision in one or both
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second eye is usually involvedwithinweeks. The loss of visual acuity is
profound and levels off below 20/400 within a fewmonths; the visual
ﬁeld defects show large centro-coecal absolute scotomas. At fundus
examination the characteristic signs include circumpapillary telan-
giectatic microangiopathy, swelling of the RNFL around the disc
(pseudoedema), and lack of leakage on ﬂuorescein angiography (in
contrast to true disc edema) [32–34]. The optic disc appears
hyperemic initially, though the axonal loss in the papillomacular
bundle leads to severe temporal pallor of the optic disc. In time, the
optic disc turns completely atrophic. Microangiopathy and fundus
changes such as RNFL swelling may be present in asymptomatic
maternal family members [35]. The endpoint of LHON is usually optic
atrophy associated with permanent loss of central vision and very
poor general visual function although there is relative sparing of
pupillary light responses [36,37]. Spontaneous recovery of visual
acuity may infrequently occur even years after onset, and the most
favourable prognostic factors are young age of onset and the 14484/
ND6 mutation [38–40].
The few LHON patients that have been studied with histopathol-
ogy showed a drastic loss of RGCs and RNFL in the retina. The post-
laminar optic nerve cross-sections display a variable loss of temporal
and central ﬁbers with different degrees of axonal sparing in the nasal
periphery and absence of inﬂammatory signs. Larger axon proﬁles are
selectively spared and found within the reactive gliotic tissue
replacing the ﬁber loss [2,41,42]. Electron microscopy reveals
ultrastructural changes in the few spared axons, such as patchy
accumulations of mitochondria and wide variability in myelin
thickness. Remarkably, there is also the persistence of degenerating
axons, long after the clinical onset of LHON [2,41]. Hence, it can be
concluded that the degenerative process continues for decades. The
retinal and optic nerve head anatomy can now be also explored in vivo
by optical coherence tomography (OCT) [5]. This technique was
recently applied to re-deﬁning with objective measures the natural
history of LHON. The acute phase (ﬁrst six months) was characterized
by loss of the papillomacular bundle temporal ﬁbers and swelling of
the adjacent RNFL in the superior/inferior quadrants [43]. The chronic
phase (after the ﬁrst six months) was characterized by severe loss of
ﬁbers in all quadrants, the nasal being the most spared [43]. OCT
evaluation of RNFL thickness also clearly distinguished patients that
experienced some degrees of visual recovery, who had a signiﬁcant
relative preservation of RNFL, from those who did not [43].
Furthermore, OCT evaluation of unaffected carriers has documented
early swelling of the papillomacular bundle in the temporal/inferior
quadrants [44].
3.1.2. LHON genetics and pathophysiology
Incomplete penetrance in homoplasmic LHON maternal lineages
and male prevalence among the affected individuals are two features
of LHON that remain a mystery and are currently matters of intense
investigation. In this regard the genetic basis of LHON is very
complex. There are three frequent pathogenic point mutations
(11778/ND4, 3460/ND1, and 14484/ND6), and a handful of other
rarer but truly pathogenic mtDNA point mutations, all affecting
subunits of complex I [2,11]. Recently, the importance of mtDNA
variation in LHON has been fully recognized. There is now solid
evidence that two subclades of haplogroup J (J1c and J2b) are
relevant to increase penetrance of the 11778/ND4 and 14484/ND6
mutations [45,46]. Furthermore, speciﬁc “private” non-synonymous
variants in mtDNA may also modify the clinical expression of LHON,
as recently shown for the recurrence of myoclonus in two LHON
pedigrees [47]. However, mtDNA pathogenic mutations and modify-
ing background are a necessary but still not sufﬁcient condition to
determine the phenotypic expression. The role of nuclear modifying
genes has been postulated and debated [48]. The X chromosome hasbeen under enquiry for a long time as a good candidate for modifying
genes, which would also explain the male prevalence. This two-locus
model was formally compatible with segregation studies in LHON
pedigrees [49] and recent linkage analysis documented two loci on X
chromosome [50,51]. However, to date no signiﬁcant genetic variants
associated with LHON were reported by the direct sequencing of
candidate genes in the X-linked loci, as well as studies on the X-
inactivation pattern in affected females failed to observe the
predicted excess of skewed inactivation [52].
The real contribution of various environmental factors proposed to
trigger LHON also remains ambiguous. Tobacco smoking and alcohol
consumption are the most likely risk factors both by analogy with
toxic and nutritional optic neuropathies and through direct investiga-
tion [2,53]. Exposures to less common toxic agents such as solvent
vapours [54], as well as head trauma, uncontrolled diabetes, or
pharmaceutical agents that interfere with mitochondrial metabolism,
such as ethambutol and antiretroviral drugs have also been reported
[2,5].
The biochemical effects of LHON mutations and the possible
pathogenic mechanisms remain areas of continuous investigation.
Every model of LHON pathophysiology assumes a defective complex I
function. Loss of energetic efﬁciency, increased oxidative stress, and
propensity to apoptotic cell death have all been variably documented
in patient's tissues and cell models of the disease [2,3]. As a
consequence, altered axonal transport of organelles and axoplasmic
stasis with swelling of axons has been proposed as key features
leading to the threshold for the acute phase of the disease [3]. The
latter is characterized by a remarkably synchronous wave of RGCs
degeneration, most likely involving apoptotic cell death [55,56]. At
this stage, the commitment to cell death might be already
irreversible, as suggested by the recent failure of therapeutic trials
designed to save the second eye by drug administration in the small
window of time separating the optic neuropathy in the ﬁrst from the
second eye [57].
3.2.1. DOA clinical features
DOA, also known as Kjer's optic neuropathy [8], can be considered
as the companion disease to LHON. DOA is characterized by a slowly
progressive bilateral loss of central vision starting in childhood and
variably progressing in adult life [2,11,58,59]. Patient examination
demonstrates centrocecal scotomas and impairment of colours vision
(tritanopia) and temporal pallor of the optic disc. The end-stage
fundus appearance of DOA is characterized by complete optic atrophy
and frequent optic disc excavation [60]. Overall, despite a remarkably
different natural history, LHON and DOA share a similar endpoint and
begin with the predominant involvement of the papillomacular
bundle [2]. Both diseases also share a remarkable variability in
penetrance [61].
The histopathology of DOA is limited to just two old studies
[62,63]. Selective loss of RGCs was reported, particularly in the
macular area, with a substantially normal appearance of the rest of the
retina. The optic nerve showed axonal loss and swelling, demyelina-
tion, and an increased content of collagen especially in the temporal
aspect (suggesting speciﬁc vulnerability of the papillomacular bundle
ﬁbers), without signs of inﬂammation.
3.2.2. DOA genetics and pathophysiology
About 60% of DOA cases are now linked to mutations in the OPA1
gene identiﬁed in 2000 [9,10]. Two further loci have been reported
(OPA4 and OPA5), but the genes involved have not yet been identiﬁed
[64,65]. The screening of numerous cohorts of DOA families of
different ethnic origin led to the identiﬁcation of a large number
(over 100) of different mutations in the OPA1 gene, including
missense, nonsense, deletion/insertion, and splicing mutations,
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region [66, see http://lbbma.univ-angers.fr]. The large majority of
OPA1 mutations are predicted to produce a premature truncated
protein and haploinsufﬁciency is the mechanism assumed to underlay
DOA in these cases, whereas missense mutations, mostly affecting the
GTPase domain, are predicted to exert a dominant-negative effect. In
general, the genotype–phenotype correlation is weak, with great
variability in both penetrance and clinical severity. As is the case for
LHON, other as yet unknown genetic or epigenetic/environmental
factors may play a role in the phenotypic expression of DOA.
The OPA1 gene encodes a 960 amino acid residue protein targeted
to mitochondria by a leader sequence, and belonging to a family of
highly conserved GTPases related to dynamin [67,68]. OPA1 has eight
mRNA isoforms resulting from alternative splicing. These are
expressed in a variety of tissues, with the highest levels found in
retina, brain, testis, heart, and muscle [69]. OPA1 is anchored to the
mitochondrial inner membrane facing the inter-membrane space and
has an important role in the mitochondrial fusion process and also in
protection from apoptosis by dealing with cytochrome c storage and
release [69–71]. Down-regulation of OPA1 using speciﬁc smallFig. 1. Human capillaries in the optic nerve head from post-mortem tissue; transmission
presented at ARVO 2001 — Ross-Cisneros FN, Win PH, Carelli V, Sadun AA, Invest Ophthalm
capillary from a LHON patient with the 11778/ND4 mutation. Note the abnormal accum
highlighted (boxed) area in (B) is represented in (C) and is enlarged to allow closer examin
endothelium. Note the cristae in the periphery of these mitochondria which appear “swolleinterference RNA leads to fragmentation of themitochondrial network
concomitantly to dissipation of the mitochondrial membrane poten-
tial and to a drastic disorganization of the cristae [70]. Recent studies
provide mounting evidence that OPA1 is also involved in OXPHOS
efﬁciency [72–74]. In particular OPA1 mutations inducing haploinsuf-
ﬁciency were shown to impair ATP synthesis in patient-derived
ﬁbroblasts when oxidative phosphorylation was driven by complex I
substrates, thus converging DOA to a ﬁnal biochemical pathway with
LHON. A similar convergence was shown by another study demon-
strating that LHON and DOA cells suffer a similar coupling defect in
respiration [74].
4. Syndromic optic neuropathies
4.1. Mitochondrial DNA-based disorders
4.1.1. LHON/dystonia/MELAS/Leigh overlapping syndrome
Optic atrophy may occur in mitochondrial encephalomyopathies
such as Myoclonic Epilepsy, Ragged-Red-Fibers (MERRF) [75] and
MELAS [76]. Furthermore, although the visual system is not usuallyelectro microscopy (TEM) [unpublished data, Ross-Cisneros, Sadun, Carelli; partially
ol Vis Sci 42 (2001) S625]. (A) Capillary from a normal age-matched control and (B) a
ulation of mitochondria in the cytoplasm of the capillary's endothelium in (B). The
ation of the numerous mitochondria circumscribing the entire extent of this capillary's
n” and display various diameters (sizes). Bar (A) 3 μm, and (C) 1 μm.
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syndrome as documented by histopathological reports [77]. MERRF
and MELAS are usually due to mtDNA point mutations affecting tRNAs
[78]. The underlying genetic defect in Leigh syndrome is very broad,
including both nuclear genes and mtDNA mutations, the latter most
often affecting complex I subunit genes [78]. The 14459/ND6
mutation is the ﬁrst mutation that showed an overlapping clinical
expression, which ranged from LHON to dystoniawith bilateral striatal
necrosis to full blown Leigh syndrome [79,80]. A few years later
another mutation at position 13513 in the ND5 subunit gene of
complex I was found associated with MELAS and later in cases with
LHON-like severe optic neuropathy [13,81,82].
A great deal of interest is now focused on this growing group of
mtDNA pointmutations affecting the ND genes, mainly ND5, ND6, and
ND1, which are associated with a syndromic overlapping LHON/
Dystonia/MELAS/Leigh syndrome [12–16,79–82]. It should be noted
that a few “LHON-plus” cases of adult-onset Leigh syndromewere also
reported in association with the “classical” 11778/ND4, 3460/ND1, or
14484/ND6 LHON mutations [83]. These observations point to a
possible common pathogenic mechanism with different degrees of
central nervous system involvement, where the LHON-like optic
neuropathy represents only the tip of the iceberg. We previously
hypothesized that the link between LHON, MELAS, and Leigh
syndromes may relate to mitochondrial angiopathy, as a shared
common feature, which implies a possible vascular involvement in the
pathophysiology of these phenotypes [2] [unpublished data, Ross-
Cisneros, Sadun, Carelli; Fig. 1].
Vascular changes in LHON are well known and their role in the
pathophysiology of the disease has been debated [2,84]. The
microangiopathy often seen in LHON may persist as a subclinical
sign over a number of years in asymptomatic family members
without the development of optic neuropathy [35,84]. During the
active phase of LHON, these vascular abnormalities may becomemore
pronounced as evidenced by arteriovenous shunting in the telan-
giectatic vascular bed, with dilatation of retinal artery branches,
tortuosity of peripapillary arterioles and occasional peripapillar
haemorrhages [5,33,34]. Once vision loss stabilizes, the vascular
abnormalities disappear. Our histopathologic investigations show
accumulations of mitochondria within smooth musculature and
endothelium, similarly to what has been described in mitochondrial
angiopathy in MELAS patients [85,86] [unpublished data, Ross-
Cisneros, Sadun, Carelli; Fig. 1]. In MELAS, a pathogenic role for
such vascular changes has been hypothesized, with particular
reference to the stroke-like episodes. Furthermore, Leigh syndrome
is also characterized by vascular changes and by small vessel
proliferation in the anatomical areas surrounding the necrotizing
lesions, which are the histological hallmark [77]. Thus, the mitochon-
drial angiopathy seems to link LHON, MELAS and Leigh syndromes,
suggesting the need to further investigate the role of vascular
pathology. LHON might be considered a small scale stroke-like
(MELAS) or Leigh syndrome acute/subacute episode that speciﬁcally
targets the optic nerve head [2].
4.2. Nuclear DNA-based disorders
4.2.1. Friedreich ataxia (FRDA) and Mohr–Tranebjaerg syndrome (MTS)
Friedreich ataxia (FRDA) is the most common autosomal recessive
hereditary ataxia characterized by spinocerebellar ataxia with
absence of deep tendon reﬂexes, dysarthria, hypertrophic cardiomyo-
pathy and scoliosis, and as possible additional features diabetes
mellitus, pes cavus, deafness and optic atrophy [87]. The genetic
defect is a GAA triplet expansion in the ﬁrst intron of the FXN gene on
chromosome 9, which may reach over 1000 repeats in both alleles,
the normal range being 27–36 repeats [88]. A minority of FRDA
patients are compound heterozygotes for the GAA triplet expansion
and a point mutation [89].The FXN gene encodes frataxin, a 210 amino acid long protein
targeted to mitochondria and directed to the inner mitochondrial
membrane, whose amount is greatly reduced by the triplet expansion.
Deﬁcient mitochondrial respiration in the heart and muscle of FRDA
patients has been documented, with a speciﬁc impairment of iron–
sulphur containing proteins such as complexes I, II and III and
aconitase [90,91]. Frataxin has also been variously implicated in iron
homeostasis, oxidative stress and the biosynthetic pathways related to
iron–sulphur containing enzymes [87].
Optic neuropathy in FRDA patients has been described in only a
few studies [92–94]. Recently, a systematic investigation of the visual
pathway involvement has been undertaken in twenty-six molecularly
conﬁrmed FRDA patients, by the integrated use of different techniques
including OCT, diffusion weighted imaging (DWI), visual ﬁelds (VF)
and pattern evoked potentials (P-VEPs) [17]. All FRDA patients
presented some degree of visual pathway involvement, but in only a
small subset was this apparent clinically. Most patients with FRDA
presented with a slowly progressive degenerative process involving
both the optic nerve and the optic radiations, as documented by the
DWI investigation [17]. In a few cases, all with severe disease and large
triplet expansion, a subacute/acute visual failure mimicking LHON
overlapped the slow progression of optic neuropathy. Thus, the
conclusion of this study was that FRDA is a mitochondrial multi-
systemic disorder for which involvement of visual pathway is
common and the pattern of visual loss and the underlying patholo-
gical mechanism clearly differs from the classical non-syndromic
mitochondrial optic neuropathies, such as LHON and OPA1-related
DOA. In FRDA there is an apparently independent involvement of the
optic radiations, which is in addition to the optic nerve/anterior
pathway [17].
A different example of a nuclear-encoded mitochondrial disease is
represented by the deafness–dystonia–optic atrophy syndrome
(Mohr–Tranebjaerg syndrome; MTS) described by Mohr [95] and
Tranebjaerg [96], which is an X-linked recessive trait due tomutations
in the deafness/dystonia peptide (DDP)/TIMM8A [97,98]. Most
mitochondrial proteins are encoded by the nuclear genome and
need to be transported through the double membranes of mitochon-
dria to reach their ﬁnal destination and be activated to their function
[99]. This process is mediated by the coordinated action of a complex
set of translocation systems of the outer (translocase of the outer
membrane or TOM) and inner (translocase of the inner membrane or
TIM) mitochondrial membranes. MTS is to date the only human
disorder affecting a TIM protein and most mutations in the TIMM8A
gene lead to a truncated protein or are large deletions with complete
loss of the protein [97,100].
TIMM8A is a small Tim protein that co-assembles with the partner
protein TIMM13 in a soluble inter-membrane space complex involved
in chaperoning the mitochondrial import of nuclear-encoded pre-
cursors proteins [99]. There is evidence that lack of TIMM8A abolishes
the assembly with TIMM13, possibly leading to a decreased rate of
TIMM23 import [101]. This latter protein is essential for import of
proteins to the matrix and may, at least hypothetically, lead in turn to
defective oxidative phosphorylation and energy production or to
other still unidentiﬁed mitochondrial dysfunctions.
Affected males with MTS have a consistent clinical expressionwith
childhood onset deafness, followed by progressive dystonia, blind-
ness, and other variable neurological features including ataxia,
spasticity, mental deterioration and behavioural disorder. However,
even within the same family with the same mutation, the timing and
the prevalence of such clinical features may vary. Females carriers are
usually unaffected, but may occasionally express a late-onset
oligosymptomatic version of MTS, suffering torticollis and writer's
cramp, or mild deafness [102]. Pathological investigations revealed
neuronal cell loss in the striate cortex, basal ganglia, and dorsal roots
of the spinal cord and posterior columns, as well as loss of RGCs and
resultant depletion of axons in the optic nerve; in the retina there is
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loss is mainly due to neurodegeneration of the visual cortex,
degeneration of the retina and the optic nerve also contribute to
visual impairment [103,104].
In this regard, MTS shows some similarity with FRDA, having a
clear involvement of the entire visual pathway, including optic
nerves, optic radiations and visual cortex. In FRDA the degenerative
process of the posterior visual pathways (optic radiations) is
probably independent and possibly asynchronous from that of the
anterior visual pathways (optic nerve). In the case of MTS, there is a
dearth of systematic investigations in a sufﬁcient number of patients
by the same integrated use of different techniques that was recently
applied to FRDA [17], and hence for MTS little is understood. In
particular, we cannot exclude that in the case of MTS the
degenerative process may start from the visual cortex (atrophy of
the visual cortex), and progress in a retrograde way (including gliosis
of the occipital poles and optic radiations), affecting only in the late
stages the retina with RGCs loss and subsequent optic nerve atrophy
[18,103].
4.2.2. Complicated hereditary spastic paraparaplegia
Hereditary spastic paraplegias (HSPs), previously known as
Strumpell–Lorrein disease, are a group of similar neurodegenerative
disorders with a clinical presentation of weakness and spasticity in the
lower limbs [105,106]. Seventeen genes, out of 41 spastic paraplegia
gene (SPG) loci mapped, have been identiﬁed, reﬂecting the large
genetic heterogeneity underlying HSPs and the blurred boundaries
with other similar disorders. HSPs are also distinguished in pure forms
and complicated variants characterized by other neurological signs
including optic atrophy [106,107]. Among the genes associated with
HSPs a few have been reported to be mitochondrial proteins, such as
paraplegin (SPG7) [18], heat shock protein 60 (SPG13) [108] and
REEP1 (SPG31) [109].
Optic atrophy may complicate the clinical picture of families with
autosomal recessive spastic paraplegia due to mutations in the SPG7
gene encoding for paraplegin [19]. Unfortunately, description of the
ophthalmological features in these patients remains elusive. It is
interesting to note that paraplegin, a mitochondrial metalloprotease
of the AAA family, has been reported to co-assemble with a
homologous protein, AFG3L2, to form a complex in the mitochondrial
inner membrane [110]. The lack of this paralegin/AFG3L2 complex
impairs complex I activity in mitochondria and increases sensitivity to
oxidative stress, a general paradigm of mitochondrial optic neuro-
pathies [2,3]. This is bolstered by studies of paraplegin-deﬁcient mice,
which show axonal swellings due to massive accumulation of
organelles and neuroﬁlaments, suggestive of impaired axonal trans-
port [111]. Similar changes were also seen in the axons of the optic
nerve from this animal model and closely resemble the ultrastructural
abnormalities described in LHON [2]. More recent studies indicated a
role of paraplegin in the quality control of mitochondria, including the
maturation of proteins involved in ribosome assembly and translation
within mitochondria [112]. Finally, paraplegin has also been involved
in the proteolytic cleavage of OPA1, although its exact role is still
questioned [113–115]. Clear-cut ultrastructural abnormalities of
mitochondria are reported in the paraplegin-deﬁcient mice, including
aberrant cristae, which are also seen in the OPA1 mutant cells from
patients with DOA, in association with the hyperfragmentation of the
mitochondrial network [70,73]. There is consensus that axonal
transport and trafﬁcking are the key features to be affected by various
mechanisms in HSPs and that long axons of the corticospinal tracts
slowly degenerate with a retrograde, “dying-back” paradigm
[105,106,112]. This raises the question as to whether for HSPs, as in
FRDA and MTS, there is an involvement of both anterior and posterior
parts of the visual pathway. Speciﬁc ophthalmologic investigations are
warranted to clarify how the optic neuropathy and visual loss develop
in HSPs.4.2.3. Disorders related to ﬁssion/fusion genes: DOA plus (OPA1), CMT2A
with optic atrophy or HMSN VI (Mfn2) and DLP1-related encephalopathy
After discovering that most DOA patients had mutations in the
OPA1 gene, several other neurodegenerative diseases have been
further associated with genetic defects affecting the mitochondrial
ﬁssion/fusion machinery. These include syndromic forms of DOA in
combination with chronic progressive external ophthalmoplegia
(CPEO) with speciﬁc missense mutations in the GTPase domain of
the OPA1 gene (DOA plus syndrome) [20,21], CMT2A with optic
atrophy or HMSN VI associated with mutations in the MFN2 gene
encoding mitofusin 2 (Mfn 2) [23,24], and, just recently, a ﬁrst case of
infantile encephalopathy described in association with mutant DLP1
gene [116].
CPEO, isolated or in a syndromic combination with other clinical
features, is the most frequent manifestation of mitochondrial
myopathy and has a heterogeneous genetic basis. It can be associated
with either mtDNA single deletions and point mutations, or with
mutations in nuclear genes resulting in mtDNA multiple deletions
[78]. At least ﬁve nuclear genes are now known to be involved in CPEO
associated with mtDNAmultiple deletions and autosomal recessive or
dominant inheritance. These are both subunits of POLG [117,118],
which is the enzyme replicating mtDNA, the mitochondrial replicative
DNA helicase Twinkle (PEO1) [119], the heart/muscle speciﬁc adenine
nucleotide translocator ANT1 [120] (SLC25A4), and ﬁnally the
thymidine phosphorylase (TP) which is involved in nucleoside pool
maintenance [121]. Among these genes, mutations in at least two of
them, i.e. POLG1 and TP, may present with a combination of deletions
and depletion of mtDNA in skeletal muscle [122,123].
The association of CPEO and mitochondrial myopathy with optic
atrophy is rare [124,125], and never reported as due to mutations in
the above mentioned genes. Thus, the recent identiﬁcation of the
same peculiar OPA1/R445H mutation in two large families described
by Treft et al. [124] and Meire et al. [125] combining the clinical
phenotype of autosomal dominant CPEO and DOA was of particular
interest [126]. Unfortunately the authors of this latter study did not
perform any muscle biopsy or mtDNA investigation on these patients
to better characterize the myopathy. A further set of seven families
with this CPEO/DOA plus phenotype were subsequently reported by
two independent studies carrying different OPA1 missense mutations
in the GTPase domain [20,21]. Among them, the OPA1/R445H
mutation was also found, and they were all associated with classic
mitochondrial myopathy with cytochrome c oxidase-negative ﬁbers
and mtDNA multiple deletions [20,21]. These two reports, document-
ing independently the molecular basis of this overlapping CPEO/DOA
plus phenotype, placed unexpectedly OPA1 as another gene
implicated in mtDNA maintenance and stability [127]. The patients
belonging to this group suffer severe sensorineural deafness,
cerebellar ataxia, axonal sensory–motor polyneuropathy, in addition
to severe early-onset optic atrophy and late CPEO/mitochondrial
myopathy. A further study recently reported that patients with
CPEO/DOA plus phenotype and mtDNA multiple deletions carried
missense mutations in the GTPase domain of the OPA1 gene in 14.2%
of a series of 21 probands investigated, being mutations in OPA1
more common than mutations in POLG2, SLC25A4, and PEO1 [128].
How these OPA1 missense mutations generate mtDNA multiple
deletions and how this produces the clinical phenotype, remains to
be fully understood.
Another recent remarkable and closely related ﬁnding was the
association of axonal CMT2A with mutations in the MFN2 gene [23].
Shortly after this report, a number of CMT2A cases with optic
atrophy, fulﬁlling the diagnostic criteria for HMSN VI, were also
described as due to mutations in the MFN2 gene [24]. In some of the
latter cases, the optic neuropathy was reported in full details and
closely resembled a benign LHON variant, similar to the cases with
the 14484/ND6 mutation that are prone to recover visual acuity after
an initial acute decline of vision [2,11]. These HMSNVI/CMT2A
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scotomas, colour vision defects and pale optic discs. They experi-
enced, over years, variable degrees of recovery of visual acuity, colour
vision and reduction of the central scotoma, reverting back to near
normal visual function. However, in contrast with recovery of visual
acuity in LHON, a late age of onset was a favourable predictive factor
in these HMSNVI/CMT2A patients, whereas those cases with child-
hood onset of visual loss had a slowly progressive course without
visual recovery, similarly to DOA patients. Thus, a remarkable link
bridges LHON and DOA to HMSNVI/CMT2A with optic neuropathy,
suggesting a continuum of optic nerve involvement in all these
clinical phenotypes. On the other hand, the axonal peripheral
neuropathy characterizing CMT2A has also recently been recognized
in a family with mutations in POLG1 gene and mtDNA multiple
deletions [129]. Furthermore, at least two studies on the functional
consequences of mutant Mfn2 protein point to mechanisms already
considered in the previous sections of this review for both LHON and
DOA [2,3]. The ﬁrst study documents an impaired mitochondrial
coupling and reduced membrane potential in ﬁbroblasts from CMT2A
patients with missense mutations in the MFN2 gene [130]. However,
a more recent study with a similar design investigating mitochon-
drial phenotype of ﬁbroblasts from CMT patients with mutant MFN2
failed to document a defective respiratory function [131]. The second
study documents impaired axonal transport of mitochondria not
related to a bioenergetic deﬁciency [132]. These authors propose that
an impairment of mitochondrial trafﬁcking would affect the longest
axonal systems, possibly underlying the pathogenesis of peripheral
neuropathy. This argument is similar to what has been discussed for
the HSPs.
Finally, after having described mutations in genes coding for the
mitochondrial fusion machinery, there is now reported a case of a
disease associated with a heterozygous dominant-negative mutation
in the dynamin-like protein 1 (DLP1), the protein involved in
mitochondrial ﬁssion [116]. Interestingly, the clinical phenotype of
this patient was a severe infantile encephalopathy, with evidence of
optic atrophy and hypoplasia, dysmyelination and abnormal gyral
pattern of cerebral cortex, and a severe respiratory dysfunction with
lactic acidosis. This patient died at the age of 37 days. Cell studies
overexpressing the DLP1 mutation clearly demonstrated a hypertu-
bulated mitochondrial network [116].
4.2.4. OPA3 gene: Costeff syndrome and DOA with cataract
Costeff syndrome is characterized by optic atrophy associated with
increased urinary excretion of 3-methylglutaconic and 3-methylglu-
taric acids [25]. In addition to optic atrophy, these patients may
display extrapyramidal signs, spasticity, ataxia, dysarthria, and
cognitive deﬁcits. Costeff syndrome has been associated with
mutations in OPA3, a gene that encodes a poorly characterized
mitochondrial protein [26]. After the initial deﬁnition of the syndrome
in an Iraqi Jew genetic isolate, mutations in OPA3 have been reported
in other populations [133]. Furthermore, at variance with the
autosomal recessive Costeff syndrome, allelic mutations in OPA3
have also been reported in families with DOA with cataract [27,28].
Recently, a mouse model of OPA3-related disease was created
recapitulating most of the clinical features observed in the patients,
but function of the OPA3 protein remains elusive [134].
5. Pathogenic mechanisms: some insights
Understanding the multiple layers of how the molecular defects
described in this review converge to tissue/cell speciﬁc neurodegen-
eration, i.e. the RGCs for optic neuropathies, has been a great challenge
and a subject of inquiry [extensively reviewed in Refs. 2–5,11].
This review has been focused on a genotype–phenotype correlation
attempting to link and compare the optic neuropathy in many
mitochondrial disorders sharing this clinical feature. Thus, it isbeyond our scope to examine in details all the experimental ﬁndings
and the proposed biochemical pathways that would translate each
molecular defect of the disorders reviewed into cell dysfunction and
ultimately the death that is remarkably speciﬁc for these neurons in
the retina. However, we would like to delineate some common
themes, and the ﬁrst point we make is that there is increasing
evidence that complex I dysfunction is part of the pathophysiology of
many mitochondrial diseases other than LHON or the mtDNA related
LHON/dystonia/MELAS/Leigh overlapping syndrome [2,3], obviously
playing a major role in their pathophysiology. Fibroblasts from DOA
patients carrying frame shift/stop codon/splicing (haploinsufﬁ-
ciency) mutations in the OPA1 gene have recently been shown to
display a defective ATP synthesis mainly when driven through
complex I substrates [73]. The pathophysiology of FRDA also
implicates a defective complex I, in addition to other enzymatic
components sharing the iron–sulphur clusters such as complex II and
III, and aconitase [90]. Furthermore, a complex I defect has been
reported in association with mutations in the paraplegin gene,
implicating this respiratory complex in the pathogenesis of HSP with
mutations in SPG7 [110]. Thus, it seems a common theme that the
optic nerve is more frequently involved in mitochondrial disorders
when complex I is affected, even if the claim that optic neuropathies
are exclusively due to complex I dysfunction cannot be a general
paradigm. In fact, we can mention cases contradicting this paradigm,
where optic atrophy is a major clinical feature in patients with either
mutations in a nuclear-encoded complex II subunit or a mutation in
an mtDNA encoded subunit of complex IV [135,136]. The opposite is
also true as many severe Leigh cases, due to nuclear defects of
complex I, reported no apparent involvement of the optic nerve.
The consequences of complex I dysfunction may go beyond the
immediate effects on energy conservation and ROS production; there
is mounting evidence tightly linking complex I dysfunction with
predisposition to apoptosis [55,56,137]. There is also a tight connec-
tion between ﬁssion/fusion, mitochondrial network dynamics, con-
trol and regulation of apoptosis [70,71,138]. There are many intricacies
of how different genetic defects, in the nuclear and in the
mitochondrial genomes, affect different biochemical systems and
cell functions implicated in mitochondrial homeostasis. However, in
many cases these may converge towards common ﬁnal pathways, one
of whichmay link complex I dysfunction and RGCs neurodegeneration
[3].
There is another overarching common theme that seems to link
some of the disorders considered in this review. The machinery
driving to mitochondrial biogenesis and mtDNA maintenance can be
either a source of pathology or provide a compensatory mechanism
for the cell. In fact, the regulation of mtDNA copy number and amount
of mitochondria remains a poorly explored issue in mitochondrial
optic neuropathies, despite some evidence that compensatory
mitochondrial biogenesis is activated by the LHON mutations,
whereas a partial reduction of mtDNA copy number has been reported
in DOA patients with OPA1 mutations [139,140]. Concerning mtDNA
maintenance, accumulation of mtDNA multiple deletions links
different phenotypes of CPEO, including the CPEO/DOA plus pheno-
type [20,21,128], as well as the involvement of peripheral nervous
system [129]. The ﬁssion/fusion dynamics and how it relates to the
accumulation of mtDNA multiple deletions is an exciting new ﬁeld to
be explored, and it promises to deliver further surprises. However, it
has also been argued that mtDNA instability in CPEO/DOA plus
patients has more to do with the late development of mitochondrial
myopathy and central nervous system involvement than with the
early onset of severe optic atrophy and deafness [127]. Unfortunately,
we still have a very poor understanding of howmitochondrial ﬁssion/
fusion is carried out and regulated in post-mitotic highly specialized
cells such as skeletal muscle and neurons [141,142]. In this regard, the
other common theme of axonal transport and trafﬁcking with
particular reference on mitochondria has been considered as a key
Fig. 2. Schematic summary of the common themes linking mitochondrial optic neuropathies.
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[106,111,112] and CMT2A/HMSNVI [132]. In summary, the control of
mitochondrial biogenesis by cells as compensation of respiratory
chain dysfunction probably involves feed-back loops and nuclear-
mitochondrial cross-talk. These systems and their messengers are far
from being understood, yet manipulations of these mechanisms hold
promise for therapeutic purposes and represent a new challenge for
the ﬁeld of mitochondrial medicine [143].
Finally, wemust recognize that our current understanding is based
on many assumptions and simpliﬁcations. We anticipate many new
insights from current investigations on the genetic basis and
pathogenic mechanisms of these disorders. For example, we already
must revise the paradigm that all mitochondrial optic neuropathies
look alike. To date, the hallmark of a mitochondrial optic neuropathy
has been the preferential involvement of the small ﬁbers of the
papillomacular bundle, which characterizes both LHON and DOA. The
reason for this super-selectivity on the ﬁbers serving central vision has
been variously hypothesized, and the most supported explanation is
that the majority of these RGCs are small, with thinly myelinated
ﬁbers and a high ﬁring rate [42]. Thus, these axons present the most
disadvantageous conditions in terms of energy requirements as
related to their capability of accommodating mitochondria (surface
area/volume) [42]. Moreover, the recent OCT studies on LHON
patients indicate that during the acute phase the RNFL is swollen in
the superior and inferior arcades, possibly because of stasis of axonal
transport and perhaps of compensatory increase in mitochondrial
numbers in the prelaminar area [43,44]. This may produce some
mechanical constrain to the thin ﬁbers of the papillomacular bundle
contributing to their early involvement and sparing the most nasal
ﬁbers. However, now the new descriptions of FRDA optic neuropathy
and visual pathology in MTS show different scenarios, with speciﬁc
patterns of neurodegeneration and involvement of the visual pathway,
in particular including optic radiations and not limited to just optic
atrophy. As we gain more details on the nature of visual loss in CMT2A
patients with MFN2 mutations or in HSPs with mutations in SPG7
gene (paraplegin), we may anticipate greater understanding of opticnerve and visual pathway involvement in mitochondrial diseases.
Understanding of the fundamental pathogenic mechanisms of
mitochondrial optic neuropathies will hopefully open an avenue to
cure and prevent blindness in these patients.
6. Conclusions
The intriguing fact that RGCs are the most common target tissue
for mitochondrial dysfunction has brought much focus on optic
neuropathies as amodel for neurodegeneration. Mitochondrial neuro-
ophthalmology has been a fruitful playground to understand some
speciﬁc mechanisms of disease, which may trigger and drive the
solution of broader questions in neurology and mitochondrial
medicine. In particular, the common themes delineated in the present
review (Fig. 2), such as the respiratory defect and increased ROS
production associated with complex I, strictly connected with
mitochondrial dynamics, both related to the axoplasmic transport in
neurons, may all converge to the ﬁnal outcome of apoptotic death of
RGCs. Furthermore, investigations of mitochondrial biogenesis and
mtDNA maintenance will be instrumental to understand cell
strategies for compensation and survival, as well as the role played
in modifying the pathogenic mechanisms. The great effort currently
invested in research in this ﬁeld is worthwhile and promising. The eye
is the only part of the central nervous system readily accessible to both
measurement and certain therapeutic strategies aimed to protect
against RGCs neurodegeneration. The eyewill likely provide awindow
that will lead to major breakthroughs for neurodegenerative diseases
in general.
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